Green Solvent Alternatives in Small-Scale Pharmaceutical Synthesis: A Comparative Life-Cycle and Cost Assessment

Abstract

Solvents account for the greater part of the mass consumed in pharmaceutical manufacture and for a correspondingly large share of its environmental burden, which has made solvent substitution the most direct lever available for reducing that burden. A substantial body of work now supports substitution decisions, principally through solvent selection guides that score candidates on safety, health and environmental criteria. This review examines how well that apparatus serves small-scale synthesis — academic laboratories, contract research organisations and small manufacturers — as distinct from the large integrated producers for whom it was built. Three arguments are developed. First, selection guides encode hazard rather than impact: they rank intrinsic properties of a substance, whereas the environmental burden of using it depends on quantity, recovery rate and disposal route, so a guide ranking is a starting point and not a conclusion. Second, life-cycle assessment supplies the missing quantity dimension but its results are dominated by the recovery assumption, and recovery is precisely the operation that small-scale users cannot perform economically — a solvent that is greener at scale may be worse in a laboratory. Third, the cost dimension has been treated qualitatively despite determining most substitution decisions in practice, and the relevant cost at small scale is disposal and requalification rather than purchase price. The review concludes that scale is the neglected variable in green solvent selection, and proposes scale-explicit guidance, recovery-rate sensitivity reporting as standard in solvent life-cycle studies, and attention to the substitution decisions that small users actually face.